Features of incidental thyroid carcinoma in Gohierri county.
J. Marti, A. Zurutuza, B. Lasa, J. Rodriguez Chinesta & M. Manrique
Introduction: In the last years, has produced an increment in diagnosis of thyroid cancer. Incidental thyroid carcinoma is defined as a tumour diagnosed after surgery for benign lesions.
Aim. The objective of this study was to assess the clinical presentation, tumour characteristics and follow-up.
Patients and methods: We analysed clinicopathologic data of incidentally thyroid carcinoma from 351 thyroid surgeries carry out in our hospital between 01-01-2005 and 31-06-2010, for uni or multinodular goiter.Surgical criteria was nodule size.
Results: Of 351 surgeries in 28 cases incidental thyroid cancer was detected of these 18 were papillary micro carcinomas (PMC), all females of 55.11±11.34 year-old (range 3779)with a size of 5.44±2.66 mm (range 19 mm);10 papillary(2 follicular variant), all women of 9.55±13.8 year-old with a size of 28.4±13.1 mm. FNA previous surgery, was carried out all patients and were negatives for malignity in all cases.Total thyroidectomy was carried out by multinodular goiter to all patients. Association with Hashimoto thyroiditis was detected in 7 patients, benign follicular lesions in 5, multicentric tumor 3 cases.Lymph-node metastasis were not disclosed in histological study.Patients with papillary tumours and multicentric PMC were treated with radioiodine.
Mean of follow up 2.35±1.56 years. No metastasis or relapses or death have been detected during follow-up.
Conclusion: Incidental thyroid carcinoma are more common in women and PMC is the main diagnosis after total thyroidectomy. Lymph-node metastasis were not found in our study. Treatment with radioiodine was performed in papillary and multifocal PMC. The prognosis in our study has been good.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector